Intellectual Property India Publishes Patent Application for 'Compositions For Inihibition Of Kras Expression And Methods Of Use Thereof' Filed by Silexion Therapeutics Ltd.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517067018 A) filed by Silexion Therapeutics Ltd., Ramat Gan, Israel, on July 14, for 'compositions for inihibition of kras expression and methods of use thereof.'

Inventor(s) include Shirvan, Mitchell; Malka Gabai, Rachel; Yaron, Michal; and Pollack-Shragai, Orit.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "Described herein are nucleic acids and compositions thereof for inhibiting expression of the KRAS oncogene, including the KRAS mutants G12D and G12V. Also described are methods for treatment of KRAS -associated cancer, such as pancreatic cancer, using the disclosed nucleic acids."

The patent application was internationally filed on Dec. 14, 2023, under International application No.PCT/IL2023/051276.

Disclaimer: Curated by HT Syndication.